230 related articles for article (PubMed ID: 37108368)
1. NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity.
Santharam MA; Shukla A; Levesque D; Kufer TA; Boisvert FM; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108368
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
3. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes.
Rodriguez GM; Bobbala D; Serrano D; Mayhue M; Champagne A; Saucier C; Steimle V; Kufer TA; Menendez A; Ramanathan S; Ilangumaran S
Oncoimmunology; 2016 Jun; 5(6):e1151593. PubMed ID: 27471621
[TBL] [Abstract][Full Text] [Related]
4. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Shukla A; Cloutier M; Appiya Santharam M; Ramanathan S; Ilangumaran S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671123
[TBL] [Abstract][Full Text] [Related]
5. NLRC5: a newly discovered MHC class I transactivator (CITA).
Meissner TB; Li A; Kobayashi KS
Microbes Infect; 2012 Jun; 14(6):477-84. PubMed ID: 22209772
[TBL] [Abstract][Full Text] [Related]
6. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.
Meissner TB; Li A; Biswas A; Lee KH; Liu YJ; Bayir E; Iliopoulos D; van den Elsen PJ; Kobayashi KS
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13794-9. PubMed ID: 20639463
[TBL] [Abstract][Full Text] [Related]
7. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
[TBL] [Abstract][Full Text] [Related]
8. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.
Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607
[TBL] [Abstract][Full Text] [Related]
9. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
10. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
11. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression.
Downs I; Vijayan S; Sidiq T; Kobayashi KS
Biofactors; 2016 Jul; 42(4):349-57. PubMed ID: 27087581
[TBL] [Abstract][Full Text] [Related]
12. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
13. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.
Staehli F; Ludigs K; Heinz LX; Seguín-Estévez Q; Ferrero I; Braun M; Schroder K; Rebsamen M; Tardivel A; Mattmann C; MacDonald HR; Romero P; Reith W; Guarda G; Tschopp J
J Immunol; 2012 Apr; 188(8):3820-8. PubMed ID: 22412192
[TBL] [Abstract][Full Text] [Related]
14. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Chelbi ST; Dang AT; Guarda G
Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
[TBL] [Abstract][Full Text] [Related]
15. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract][Full Text] [Related]
16. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.
Robbins GR; Truax AD; Davis BK; Zhang L; Brickey WJ; Ting JP
J Biol Chem; 2012 Jul; 287(29):24294-303. PubMed ID: 22645137
[TBL] [Abstract][Full Text] [Related]
17. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.
Meissner TB; Li A; Liu YJ; Gagnon E; Kobayashi KS
Biochem Biophys Res Commun; 2012 Feb; 418(4):786-91. PubMed ID: 22310711
[TBL] [Abstract][Full Text] [Related]
18. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner.
Neerincx A; Rodriguez GM; Steimle V; Kufer TA
J Immunol; 2012 May; 188(10):4940-50. PubMed ID: 22490867
[TBL] [Abstract][Full Text] [Related]
19. Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells.
Guo X; Liu T; Shi H; Wang J; Ji P; Wang H; Hou Y; Tan RX; Li E
J Virol; 2015 Aug; 89(15):7636-45. PubMed ID: 25972545
[TBL] [Abstract][Full Text] [Related]
20. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
